Q2 2025 Zealand Pharma A/S Earnings Call Transcript
Key Points
- Zealand Pharma AS (ZLDPF) has a strong financial position with a cash reserve of DKK16.6 billion, bolstered by a significant upfront payment from Roche.
- The company is advancing its obesity pipeline with promising programs like petrelintide and survodutide, backed by strong partners such as Roche and Boehringer Ingelheim.
- Zealand Pharma AS (ZLDPF) has made strategic leadership appointments to drive innovation and development, including a new Chief Scientific Officer and Chief Development Officer.
- The collaboration with Roche is progressing well, with plans to initiate Phase III trials for petrelintide monotherapy in the second half of 2026.
- The company is focused on developing more tolerable and patient-friendly obesity treatments, aiming for weight loss in the range of 10% to 20% with fewer gastrointestinal side effects.
- There are concerns about the tolerability and side effect profile of current obesity treatments, which may impact patient adherence and satisfaction.
- The company faces challenges in differentiating its amylin-based therapies from existing GLP-1-based treatments, particularly in terms of cardiovascular benefits.
- Zealand Pharma AS (ZLDPF) has not yet resolved manufacturing issues for its rare disease program, dasiglucagon, which could delay product availability.
- The market for obesity treatments is highly competitive, with significant focus on achieving the highest weight loss, which may overshadow Zealand Pharma's approach.
- There is uncertainty regarding the long-term efficacy and durability of weight loss with amylin-based therapies compared to established GLP-1 treatments.
Good day, and thank you for standing by. Welcome to the Zealand Pharma interim report half year 2025 conference call. (Operator Instructions). Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Adam Langer, Vice President, Investor Relations. Please go ahead.
/- -
Thank you, operator, and thank you to everyone for joining us today to discuss Zealand Pharma's results for the first six months of 2025. You can find the related company announcement on our website at zealandpharma.com. As described on slide 2, I caution listeners that during this call, we will be making forward-looking statements that are subject to risks and uncertainties.
Turning to slide 3 and today's agenda. With me today are the following members of Zealand Pharma's management team. Adam Steensberg, President and Chief Executive Officer; Henriette Wennicke, Chief Financial Officer; and David Kendall, Chief
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
